Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 12, 2002 - Issue 2
Submit an article Journal homepage
63
Views
8
CrossRef citations to date
0
Altmetric
Review

Therapeutical application of voltage-gated calcium channel modulators

Andrei A Kochegarov Institute for Brain Aging and Dementia, University of California, Irvine, CA 92697, USA. [email protected]
Pages 243-287 | Published online: 25 Feb 2005

Bibliography

  • RINGERS: Concerning the influence exerted by each of the constituents of the blood on the contraction of the ventricle. Physic] (1882) 3:380–393.
  • HEILBRUNN LV, WIERCINSKI FJ: The action of various cations on muscle protoplasm. J. Cellular Comp. Physic]. (1947) 29:15–32.
  • BERRIDGE MJ, LIPP P, BOOTMAN MD: The versatility and universality of calcium signalling. Nat. Rev Mol. Cell Biol. (2000) ):11–21. most recent and comprehensive review.
  • BRINI M, CARAFOLI E: Calcium signalling: a historical account, recent developments and future perspectives. Cell Md. Life Sci. (2000) 57(3):354–370.
  • ••The most recent and comprehensivereview.
  • STRIESSNIG J: Pharmacology, Structureand Function of Cardiac L-Type Ca2+-Channels. Cell Physic]. Biochem. (1999) 9:242–269.
  • CATTERALL WA: Structure and regulation of voltage-gated Ca2+ channels. Ann. Rev Cell Dev. Biol. (2000) 16:521–555.
  • HOFMANN E LACINOVA L, KLUGBAUER N: Voltage-dependent calcium channels: From Structure to function. Rev Physic]. Biochem. Pharmacol. (1999) 139:33–87.
  • HOFMANN E KLUGBAUER N: Structure of the voltage-dependent L-type calcium channel. In: Pharmacology of Ionic Channel Function: Activators and Inhibitors. Endo, Y Kurachi, M Mishina, Springer Verlag (Eds) (2000):87–117.
  • LACINOVA L, HOFMANN F: Voltage-Dependent Calcium Channels. In: Heart Physiology and Pathophysiology. Fourth Edition, Academic Press, (2000:247–257.
  • ERTEL EA, CAMPBELL KE HARPOLD MM et al.: Nomenclature of voltage-gated calcium channels [letter]. Neuron (2000) 25(3):533–535.
  • NOWYCKY MC, FOX AE TSIEN RW: Three types of neuronal calcium channel with different calcium agonist sensitivity. Nature (1985) 316:440–446.
  • BOURINET E, SOONG TW, SUTTON K et al.: Splicing of alp subunit gene generates phenotypic variants of P- and Q-type calcium channels. Nat. Neurosci. (1999) 2:407–415.
  • BEAM K: Calcium channel splicing: mind your Ps and Qs. Nat. Neurosci. (1999) 2(5):393–394.
  • HILLYARD DR, MONJE VD, MINTZ IM et al.: A new conus peptide ligand for mammalian presynaptic Ca2+ channels. Neuron (1992) 9:69–77.
  • ZHANG JF, RANDALL AD, ELLINOR PT etal.: Distinctive pharmacology and kinetics of cloned neuronal Ca2+ channels and their possible counterparts in mammalian CNS neurons. (1993) 32:1075–1088.
  • TOTTENE A, MORETTI A, D: Functional diversity of P-type and R-type calcium channels in rat cerebellar neurons. j Neurosci. (1996) 16:6353–6363.
  • ALBILLOS A, NEHER E, MOSER T: R-Type Ca2+ Channels Are Coupled to the Rapid Component of Secretion in Mouse Adrenal Slice Chromaffin Cells. j Neurosci (2000) 20: 8323–8330.
  • WU L-G, BORST JGG, SAKMANN B: R-type Ca2+ currents evoke transmitter release at a rat central synapse. Proc. Natl. Acad. Li. USA (1998) 95:4720–4725.
  • VAJNA R, KLOCKNER U, PEREVERZEV A et al.: Functional coupling between R-type' Ca2+ channels and insulin secretion in the insulinoma cell line INS-1. Eur. j Biochem. (2001) 268:1066–1075.
  • NEWCOMB R, SZOKE B, PALMA A, WANG G: Selective peptide antagonist of the class E calcium channel from the venom of the tarantula Hysterocrates gigas. Biochemistry (1998) 37(44):15353–15362.
  • NEWCOMB R, CHEN X, DEAN R etal.:SNX-482: A Novel Class E Calcium Channel Antagonist from Tarantula Venom. CNS Drug Rev (2000) 6(2):153–173.
  • LACINOVA L, KLUGBAUER N, HOFMANN F.: Low voltage activated calcium channels: from genes tofunction. Contents of General Physic]. Biophys. (2000) 19(2):121–136.
  • LACINOVA L, KLUGBAUER N, HOFMANN F: Regulation of the calcium channel alpha(1G) subunit by divalent cations and organic blockers. Neuropharmarology (2000) 39(7):1254–1266.
  • GURNETT CH, CAMPBELL K: Transmembrane Auxiliary Subunits of Voltage-dependent Ion Channels. j Biol. Chem. (1996) 271(45):27975–27978.
  • MEIR A, DOLPHIN AC: Known calcium channel alphal subunits can form low threshold small conductance channels with similarities to native T-type channels. Neuron (1998) 20(2):341–351.
  • HESS P, LANSMAN JB, TSIEN RW: Calcium channel selectivity for divalent and monovalent cations: voltage and concentration dependence of single channel current in ventricular heart cells. j Gen. Physic]. (1986) 88:293–319.
  • TSIEN RW, HESS P, MCCLESKEY EW, RL: Calcium channels: mechanisms of selectivity, permeation and block. Ann. Rev Biophys. Chem. (1987) 16:265–290.
  • MCCLESKEY EW, ALMERS W: The Ca channel in skeletal muscle is a large pore. Proc. Nati Acad. Sci. USA (1985) 82:7149–7153.
  • ARMSTRONG CM, NEYTON J: Ion permeation through calcium channels: a one site model. Ann. NY Acad. Sci. (1991) 635:18–25.
  • NOWYCKY MC, FOX AE TSIEN RW: Long-opening mode of gating of neuronal calcium channels and its promotion by the dihydropyridine calcium agonist Bay K 8644. Proc. Natl. Acad. Sci. USA 82:7149–7153.
  • CORRY B, ALLEN TW, KUYUCAK S, CHUNG SH: Mechanisms of Permeation and Selectivity in Calcium Channels. Biophys. (2001) 80(1):195–214.
  • KUO CC, HESS P: Ion permeation through the L-type Ca2+ channel in rat phaeochromocytoma cells: two sets of ion binding sites in the pore. I Physic]. (1993) 466:629–655.
  • ALMERS W, MCCLESKEY EW, PALADE PT: A non-selective cation conductance in frog muscle membrane blocked by micromolar external calcium ions. I Physic]. (1984) 353:565–583.
  • FONTERIZ RI, GARCIA-SANCHO J, GANDIA L etal.: Permeation and inactivation by calcium and manganese of bovine adrenal chromaffln cell calcium channels. Am. j Physic]. (1992) 263(4):C818–824.
  • YANG J, ELLINOR PT, SATHER WA, ZHANG, JF, TSIEN RW: Molecular determinants of Ca2+ selectivity and ion permeation in L-type Ca2+ channels. Nature (1993) 366(6451):158–161.
  • KERCHNER GA, CANZONIERO LM, YU SP, LING C, CHOI DW: Zn2+ current is mediated by voltage-gated Ca2+ channels and enhanced by extracellular acidity in mouse cortical neurones. j Physic]. (2000) 528 (1) :39–52.
  • VEGA MT, VILLALOBOS C, GARRIDO B et al.: Permeation by zinc of bovine chromaffin cell calcium channels: relevance to secretion. Pllugers Archiv. Eur. J Physic]. (1994) 429(2):231–239.
  • SHIBUYA I, DOUGLAS WW: Indicationsfrom Mn-quenching of Fura-2 fluorescence in melanotrophs that dopamine and close Ca channels that are spontaneously open but not those opened high0; and that Cd preferentiallyblocks the latter. Cell Calcium (1993) 14(1):33–44.
  • TOMSIG JL, SUSZKIW JB: Permeation of Pb2+ through calcium channels: fura-2 measurements of voltage- and dihydropyridine-sensitive Pb2+ entry in isolated bovine chromaffin cells. Biochim. Biophys. Acta (1991) 1069(2):197–200.
  • SOONG TW, STEA A, HODSON CD, DUBEL SJ: Structure and functional expression of a member of the low voltage-activated calcium channel family. Science (1993) 260(5111):1133–1136.
  • LACINOVA L, KLUGBAUER N, HOFMANN F: Low voltage activated calcium channels: from genes to function. General Physiol. Biophys. (2000) 19(2):121–136.
  • MLINAR B, ENYEART JJ: Block of current through T-type calcium channels by trivalent metal cations and nickel in neural rat and human cells. I Physiol. (1993) 469:639–652.
  • WINEGAR, BD. KELLY R, LANSMAN JB: Block of current through single calcium channels by Fe, Co, and Ni. j Gen. Physiol. (1991) 97:351–367.
  • WINEGAR BD, LANSMAN JB: Voltage-dependent block by zinc of single dihydropyridine-sensitive calcium channels in mouse C2 myotubes. j Physiol. (1990) 425:563–578.
  • WEINSBERG 1 BICKMEYER U, WIEGAND H: Effects of inorganic mercury Hg2+ on calcium channel currents and catecholamine release from bovine chromaffin cells. Arch. Toxicol. (1995) 69(3):191–196.
  • SUN LR, SUSZKIW JB: Extracellular inhibition and intracellular enhancement of Ca2+ currents by Pb2+ in bovine adrenal chromaffin cells. 1. Neurophysiol. (1995) 74(2):574–581.
  • ZIMMERMAN AN, HOLSMANN WC: Paradoxical influence of calcium ions on the permeability of the cell membranes of the isolated rat heart. Nature (1966) 211(49):646–647.
  • GANOTE CE, NAYLERWG: Contracture and the calcium paradox. j Mal. Cell Cardiol. (1985) 17(8):733–745.
  • DALY MJ, ELZ JS, NAYLER WG: Contracture and the calcium paradox in the rat heart. Circ. Res. (1987) 61(4):560–569.
  • GRIN WALD PM, NAYLER WG: Calcium entry in the calcium paradox. 1. Ma Cell. Cardiol. (1981) 13(10):867–880.
  • TUNSTALL J, BUSSELEN P, RODRIGO GC, CHAPMAN RA: Pathways for the movements of ions during calcium-free perfusion and the induction of the 'calcium paradox'. J. MoL Cell Cardiol. (1986) 18(3):241–254.
  • SCHNEIDER MF, CHANDLER WK: Voltage dependent charge movement of skeletal muscle: a possible step in excitation-contraction coupling. Nature (1973) 242:244–246.
  • GARCIA J, NAKAI J, IMOTO K, BEAM KG: Role of S4 segments and the leucine heptad motif in the activation of an L-type calcium channel. Biophys. 1 (1997) 72(6):2515–2523.
  • ZHANG JF, ELLINOR PT, ALDRICH RW, TSIEN RW: Molecular determinants of voltage-dependent inactivation in calcium channels. Nature (1994) 372:97–100.
  • HERING S, BERJUKOW S, SOKOLOV, MARKSTEINER R: Molecular determinants of inactivation in voltage-gated Ca2+ channels. I Physiol. (2000) 528(2):237–249.
  • LEE KS, MARBAN E, TSIEN RW: Inactivation of calcium channels in mammalian heart cells: joint dependence on membrane potential and intracellular calcium. I Physiol. (1985) 364:395–411.
  • NEELY A, OLCESE R, WEI X, L, STEFANI E: Calcium-dependent inactivation of a cloned cardiac calcium channel alphal subunit (al C) expressed in Xenopus oo-cytes. Biophys. I (1994) 65:1895–1903.
  • SOLDATOV NM: Genomic structure of L-type Ca2+ channel. Genomics (1994) 22:77–87.
  • ZOHLKE RD, REUTER H: Ca2±-sensitive of L-type Ca2+ channels depends on multiple cytoplasmic amino acid sequences of the aic subunit. Proc. Natl. Acad. Li. USA (1998) 95:3287–3294.
  • PETERSON BZ, DEMARIA CD, ADELMAN J, YUE DT: Calmodulin is the Ca2+ sensor for Ca2±-dependent inactivation of L-type calcium channels. Neuron (1999) 22:549–558.
  • QIN N, OLCESE R, BRANSBY M, LIN, BIRNBAUMER L: Ca2+ induced of the cardiac Ca2+ channel depends on calmodulin. Proc. Nati Acad.. USA (1999) 96:2435–2438.
  • GURNEY AM, CHARNET P, PYE JM, NARGEOT J: Augmentation of cardiac calcium current by flash photolysis of intracellular cage- Ca2±molecules. Nature (1989) 341:65–68.
  • MCCARRON JG, MCGEOWN JG, REARDON S, IKEBE M etal.: Calcium-dependent enhancement of calcium current in smooth muscle by calmodulin-dependent protein kinase II. Nature (1992) 357:74–77.
  • ANDERSON ME, BRAUN AP SCHULMAN H, PREMACK BA: Multifunctional Ca2+/calmodulin-dependent protein kinase mediates Ca2+ induced enhancement of the L-type Ca2+ current in rabbit ventricular myocytes. Circ. Res. (1994) 75:854–861.
  • YUAN W, BERS DM: Ca-dependent facilitation of cardiac Ca current is due to Ca-calmodulin-dependent protein kinase. Am. 1. Physiol. (1994) 267:H982–H93.
  • XIAO R-P, CHENG H, LEDERER WJ, SUZUKI T, LAKATTA EG: Dual regulation of Ca2±/calmodulin-dependent kinase II activity by membrane voltage and by calcium influx. Proc. Nati Acad. Sci. USA (1994) 91:9659–9663.
  • GAO T, CHIEN AJ, HOSEY MM: Complexes of the al C and 13 sub-units generate the necessary signal for membrane targeting of class C L-type calcium channels. J. Biol. Chem. (1999) 274:2137–2144.
  • BRICE N L, BERROW NS, CAMPBELL et al.: Importance of the different 13 subunits in the membrane expression of the a 1A and a 2 calcium channel subunits: studies using a depolarisation-sensitive a 1A antibody. Eur. j Neurosci. (1997) 9:749–759.
  • MITTERDORFER J, SINNEGGER MJ, GRABNER M, STRIESSNIG J, GLOSSMANN H: Coordination of Ca2+ by the pore region glutamates is essential for high-affinity dihydropyridine binding to the cardiac Ca2+ channel al subunit. Biochemistry (1995) 34:9350–9355.
  • SINGER D, BIEL M, LOTAN I et aL: The roles of the subunits in the function of the calcium channel. Science (1991) 253:1553–1557.
  • CHIEN AJ, CARR KM, SHIROKOV RE, RIOS E, HOSEY MM: Identification of palmitoylation sites within the L-type calcium channel Ina subunit and effects on channel function. 1. Biol. Chem. (1996) 271:26465–26468.
  • QIN N, PLATANO D, OLCESE R etal.: Unique regulatory properties of the Type 2a Ca2+ channel beta subunit caused by palmitoylation. Proc. Natl. Acad. Sd. USA (1998) 95:4690–4695.
  • WET XY:Heterologous regulation of the cardiac Ca2+ channel al subunit by skeletal muscle 13 and y subunits. Implications for the structure of cardiac L-type Ca2+ channels. J. Biol. Chem. (1991) 266:21943–21947.
  • BIEL M, RUTH P, BOSSE E et al: Primarystructure and functional expression of a high voltage activated calcium channel from rabbit lung. FEBS Lett. (1990) 269:409–412.
  • CATTERALL WA: Structure and functionof neuronal Ca2+ channels and their role in neurotransmitter release. Cell Cakium (1998) 24(5-6):307–323.
  • •Comprehensive review on the involvement of CCs in neurotransmitter release.
  • SRINIVASAN J, SCHACHNER M, CATTERALL WA: Interaction of voltage-gated sodium channels with the extracellular matrix molecules tenascin-C and tenascin-R. Proc. Nat. Acad. Sci. USA (1998) 95(26):15753–15757.
  • DE WAARD M, CAMPBELL KP: Subunit regulation of the neuronal alA Ca2+ channel expressed in Xenopus oocytes. Physiol (1995) 485:619–634.
  • GEE NS, BROWN JP, DISSANAYAKE VUK et al.: The novel anticonvulsant drug, gabapentin (neurontin), binds to the a28 subunit of a calcium channel. j. Biol. Chem. (1996) 271:5768–5776.
  • BROWN JP, DISSANAYAKE VU, BRIGGS AR, MILIC MR, GEE NS: Isolation of the PH gabapentin-binding protein/a28 calcium channel subunit from porcine brain: Development of a radioligand binding assay for a28 subunits using [31-111eucine. Anal. Biochem. (1998) 15:236–243.
  • KLUGBAUER N, DAT S, SPECHT V et al.IA family of y-like calcium channel subunits. FEBS Lett. (2000) 470(2):189–197.
  • RIOS E, BRUM G: Involvement of dihydropyridine receptors in excitation-contraction coupling in skeletal muscle. Nature (1987) 325(6106):717–720.
  • FRANZINI-ARMSTRONG C, JORGENSEN K: Structure and development of E-C coupling units in muscle. Ann. Rev Physic] (1994) 56:509–534.
  • SCHNEIDER MF: Control of calcium release in functioning skeletal muscle fibers. Ann. Rev Physiol. (1994) 56:463–484.
  • ARMSTRONG C, BEZANILLA FM, HOROWICZ P: Twitches in the presence of ethylene glycol bis(-aminoethyl ether)-N,N'-tetracetic acid. Biochim. Biophys. Acta (1972) 267:605–608.
  • RIOS E, MA J, GONZALEZ A: The mechanical hypothesis of excitation-contraction (EC) coupling in skeletal muscle. J. Muscle Res. Cell Motility (1991) 12:127–135.
  • DE JONGH KS, MERRICK DK, CATTERALL WA: Subunits of purified calcium channels: a 212-kDa form of al and partial amino acid sequence of a phosphorylation site of an independent beta subunit. Proc. Natl. Acad. ScL USA (1989) 86:8585–8589.
  • BRUM G, STEFANI E, RIOS E: Simultaneous measurements of Ca2+ currents and intracellular Ca2+ concentrations in single skeletal muscle fibers of the frog. Canadian J Physiol Pharmacol (1987) 65(4):681–685.
  • TANABE T, BEAM KG, ADAMS BA et al Regions of the skeletal muscle dihydropyridine receptor critical for excitation-contraction coupling. Nature (1990) 346(6284):567–569.
  • NAKAT J, TANABE T, KONNO T, ADAMS B, BEAM KG: Localization in the II-III Loop of the Dihydropyridine Receptor of a Sequence Critical for Excitation-Contraction Coupling. j Biol. Chem. (1998) 273(39):24983–24986.
  • LEONG P, MACLENNAN DH: The Cytoplasmic Loops between Domains II and III and Domains III and IV in the Skeletal Muscle Dihydropyridine Receptor Bind to a Contiguous Site in the Skeletal Muscle Ryanodine Receptor. J. Biol. Chem. (1998) 273:29958–29964.
  • FABIATO A: Simulated calcium current can both cause calcium loading in and trigger calcium release from the sarcoplasmic reticulum of a skinned canine cardiac Purkinje cell. I Gen. Physiol (1985) 85:291–320.
  • NABAUER M, CALLEWAERT G, CLEEMANN L, MORAD M: Regulation of calcium release is gated by calcium current, not gating charge, in cardiac myocytes. Science (1989) 244(4906):800–803.
  • OZ M, FRANK GB: The effects of verapamil on tetanic contractions of frog's skeletal muscle. Comparative Biochem. Physiol (1994) 107(3):321–329.
  • WU LG, WESTENBROEK RE, BORST JGG et al: Calcium channel types with distinct presynaptic localization couple differentially to transmitter release in single calyx-type synapses. J. Neurosci. (1999) 19(2):726–736.
  • SIDDHOF TC: The synaptic vesicle cycle: a cascade of protein-protein interactions. Nature (1995) 375:645–653.
  • BAJJALIEH SM, SCHELLER RH: The biochemistry of neurotransmitter secretion. Biol. Chem. (1995) 270:1971–1974.
  • YOKOYAMA CT, SHENG Z-H, CATTERALL WA: Phosphorylation of the synaptic protein interaction site on N-type calcium channels inhibits interactions with SNARE proteins. J. Neurosci. (1997) 17:6929–6938.
  • MOCHIDA S, SHENG Z-H, BAKER C, KOBAYASHI H, CATTERALL WA: Inhibition of neurotransmission by peptides containing the synaptic protein interaction site of N-type Ca2+ channels. Neuron (1996) 17:781–788.
  • JEN J: Calcium channelopathies in the central nervous system. Cun: Opin. Neurobiol (1999) 9:274–280.
  • MISSIAEN L, ROBBERECHT W,VAN DEN BOSCH L et al: Abnormal intracellular Ca2+ homeostasis and disease. Cell Calcium (2000) 28(1):1–21.
  • CELESTA GG: Disorders of membrane channels or channelopathies.. (2001) 112(1):2–18.
  • FLUCHER BE, ANDREWS SB, FLEISCHER S et al: Triad formation: organization and function of the sarcoplasmic reticulum calcium release channel and triadin in normal and dysgenic muscle in vitro. J. Cell Biol. (1993) 123:1161–1174.
  • POWELL JA, PETHERBRIDGE L, FLUCHER BE: Immortalized cell lines from dysgenic skeletal muscle: evidence for triad formation without dihydropyridine receptor a subunits. Biophys. J. (1995) 68(2)A:415.
  • HOFFMAN EP, LEHMANN-HORN F, RODEL R: Overexcited or inactive: ion channels in muscle disease. Cell (1995) 80(5):681–686.
  • OPHOFF RA, TERWINDT GM, MN et al.: Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell (1996) 87:543–552.
  • KRAUS RL, SINNEGGER MJ, GLOSSMANN H, HERING S, STRIESSNIG J: Familial hemiplegic migraine mutations change aA Ca2+ channel kinetics. J. Biol. Chem. (1998) 273:5586–5590.
  • HANS M, LUVISETTO S, WILLIAMS ME, SPAGNOLO M et al: Functional consequences of mutations in the human alA calcium channel subunit linked to familial hemiplegic migraine. J. Neurosci. (1999) 19:1610–1619.
  • DUCROS A, DENIER C, JOUTEL A et al.: Recurrence of the T666M calcium channel CACNA1A gene mutation in familial hemiplegic migraine with progressive cerebellar ataxia. Am. J. Hum. Genet. (1999) 64:89–98.
  • MILLER RJ: Rocking and rolling with Ca2+ channels. Trends Neurosci. (2001) 24(8)445–449.
  • ••The most recent and comprehensivereview.
  • BRANDT T, STRUPP M: Episodic ataxia Type 1 and 2 (familial periodic ataxia/ vertigo). Audiology Neuro-Otology (1997) 2(6):373–383.
  • TAKAMORI M: An autoimmune channelopathy associated with cancer: Lambert-Eaton myasthenic syndrome. Intern. Med. (1999) 38(2):86–96.
  • BECH-HANSEN NT, NAYLOR MJ, MAYBAUM TA, PEARCE WG: Loss-of-function mutations in a calcium-channel al-subunit gene in Xp11.23 cause incomplete X-linked congenital stationary night blindness. Nat. Genet. (1998) 19(3):264–267.
  • STROM TM, NYAKATURA G, APFELSTEDT-SYLLA E, HELLEBRAND H: An L-type calcium-channel gene mutated in incomplete X-linked congenital stationary night blindness. Nat. Genet. (1998) 19(3):260–263.
  • YAGI T, MACLEISH P: Ionic of monkey solitary cone inner segments. J. Neurophysiol. (1994) 71:656–665.
  • TAYLOR WR, MORGANS C: and properties of voltage-gated calcium channels in cone photoreceptors of belangeri. Vis. Neurosci (1998) 15:541–552.
  • GREGG RG, MESSING A, STUBE C et al.: Absence of the 13 subunit (cchbl) of the skeletal muscle dihydropyridine receptor alters expression of the al subunit and eliminates excitation-contraction coupling. Proc. Natl. Acad. Sci. USA (1996) 93:13961–13966.
  • BURGESS DL, JONES JM, MEISLER MH, NOEBELS JL: Mutation of the Ca2+ channel 13 subunit gene Cchb4 is associated with ataxia and seizures in the lethargic (1h) mouse. Cell (1997) 88:385–392.
  • LETTS VA, FELIX R, BIDDLECOME GH et al.: The mouse stargazer gene encodes a neuronal Ca2+ -channel 7 subunit. Nat. Genet. (1998) 19:340–347.
  • HOLZ GG, RANE SG, DUNLAP K: GTP-binding proteins mediate transmitter inhibition of voltage-dependent calcium channels. Nature (1986) 319:670–672.
  • IKEDA SR, SCHOFIELD G: Somatostatin blocks a calcium current in rat sympathetic ganglion neurones. J. Physiol (1989) 409:221–240.
  • BEAN BP: Neurotransmitter inhibition of neuronal calcium channels by changes in channel voltage dependence. Nature (1989) 340:153–156.
  • ZAMPONI GW, SNUTCH TP: Modulation of voltage-dependent calcium channels by G proteins. Curr. Opin. Neurobiol (1998) 8:351–356.
  • DOLPHIN AC: Mechanisms of modulation of voltage-dependent calcium channels by G proteins. J. Physiol. (1998) 506:3–11.
  • WICKMAN K, CLAPHAM DE: Ion channel regulation by G proteins. Physiol Rev (1995) 75:865–885.
  • LIPSCOMBE D, KONGSAMUT S, TSIEN RW: a-adrenergic inhibition of sympathetic neurotransmitter release mediated by modulation of N-type calcium-channel gating. Nature (1989) 340:639–642.
  • BERNHEIM L, MATHIE A, HILLE B: Characterization of muscarinic receptor subtype inhibiting Ca 2+ current and M current in rat sympathetic neurons. Proc. Natl. Acad. Li. USA (1992) 89:9544–9548.
  • HILLE B: Modulation of ion-channel function by G-protein-coupled receptors. Trend s Neurosci. (1994) 17:531–536.
  • MILLER RJ: Receptor-mediated regulation of calcium channels and neurotransmitter release. FASEB J. (1990) 4:3291–3299.
  • SHAPIRO MS, HILLE B: Substance P and somatostatin inhibit calcium channels in rat sympathetic neurons via different G protein pathways. Neuron (1993) 10:11–20.
  • EWALD DA, PANG I-H, STERNWEIS PC, MILLER RJ: Differential G-protein-mediated coupling of neurotransmitter receptors to Ca2+ channels in rat dorsal ganglion neurons in vitro. Neuron (1989) 2:1185–1193.
  • BEECH DJ, BERNHEIM L, HILLE B: Pertussis toxin and voltage dependence distinguish multiple pathways modulating calcium channels of rat sympathetic neurons. Neuron (1992) 8:97–106.
  • CAULFIELD MP, JONES S, VALLIS Y et al.: Muscarinic M-current inhibition via G aq/11 and a-adrenoreceptor inhibition of Ca2+ current via G ao in rat sympathetic neurons. J. Physiol (1994) 477:415–422.
  • DOLPHIN AC: Voltage-dependent calcium channels and their modulation by neurotransmitters and G proteins. Exp. Physiol (1995) 80:1–36.
  • FORSCHER P, OXFORD GS, SCHULZ: Noradrenaline modulates calcium channels in avian dorsal root ganglion cells through tight receptor-channel coupling. J. Physiol (1986) 379:131–144.
  • HERLITZE S, GARCIA DE, MACKIE K et al.:Modulation of Ca2+ channels by G-protein subunits. Nature (1996) 280:258–262.
  • IKEDA SR: Voltage-dependent modulation of N-type calcium channels by G-protein subunits. Nature (1996) 380:255–258.
  • ZAMPONI GW, BOURINET E, NELSON D, NARGEOT J, SNUTCH TP: Crosstalk between G proteins and protein kinase C mediated by the calcium channel al subunit. Nature (1997) 385:242–246.
  • DEWAARD M, LIU H, WALKER D et al: Direct binding of G protein complex to voltage-dependent calcium channels. Nature (1997) 385:446–450.
  • PAGE KM, STEPHENS GJ, BERROW NS, DOLPHIN AC: The intracellular loop between domains I and II of the B-type calcium channel confers aspects of G protein sensitivity to the E-type calcium channel. J. Neurosci. (1997) 17:1330–1338.
  • CAMPBELL V, BERROW NS, FITZGERALD EM, BRICKLEY K, DOLPHIN AC: Inhibition of the interaction of G protein Go with calcium channels by the calcium channel b-subunit rat neurones. ..I Physiol. (1995) 485:365–372.
  • BOURINET E, SOONG TW, STEA A, SNUTCH TP: Determinants of the G-protein dependent opioid modulation of neuronal calcium channels. Proc. Natl. Acad. Sci. USA (1996) 93:1486–1491.
  • CANTI C, BOGDANOV Y, DOLPHIN AC: Interaction between G proteins and accessory subunits in the regulation of 1B calcium channels in Xenopus oocytes. Physiol. (2000) 527(3):419–432.
  • ZAMPONI GW, BOURINET E, NELSON D, NARGEOT J, SNUTCH TP: Crosstalk between G proteins and protein kinase C mediated by the calcium channel al subunit. Nature (1997) 385:242–246.
  • TOTH PT, SHEKTER LR, MA GH, PHILLIPSON LH, MILLER RJ: Selective G-protein regulation of neuronal calcium channels. j Neurosci. (1996) 16:4617–4624.
  • MEIR A, BELL DC, STEPHENS GJ, PAGE KM, DOLPHIN AC: Calcium channel 13 subunit promotes voltage-dependent inhibition of alB by Gbg. Biophys. J (2000) 79:731–746.
  • ZHANG JF, ELLINOR PT, ALDRICH RW, TSIEN RW: Multiple structural elements in voltage-dependent Ca2+ channels support their inhibition by G proteins. Neuron (1996) 17:991–1003.
  • QIN N, PLATANO D, OLCESE R, STEFANI E, BIRNBAUMER L: Direct interaction of Gh with a C-terminal binding domain of the calcium channel al subunit is responsible for channel inhibition by G protein coupled receptors. Proc. Natl. Acad. Sci. USA (1997) 94:8866–8871.
  • REUTER H: Localization of beta adrenergic receptors, and effects of noradrenaline and cyclic nucleotides on action potentials, ionic currents and tension in mammalian cardiac muscle. j Physiol. (1974) 242:429–451.
  • BEAN BP, NOWYCKY MC, TSIEN RW: B-adrenergic modulation of calcium channels in frog ventricular heart cells. Nature (1984) 307(5949):371–375.
  • ARREOLA J, CALVO J, GARCIA MC, SANCHEZ JA: Modulation of calcium channels of twitch skeletal muscle fibres of the frog by adrenaline and cyclic adenosine monophosphate. I Physiol. (1987) 393:307–330.
  • MITTERDORFER J, FROSCHMAYR M, GRABNER M et al.: Identification of PKA sites in the carboxyl terminus of L-type calcium channel alphal subunits. Biochemistry (1996) 35:9400–9406.
  • DE JONGH KS, MURPHY BJ, COLVIN AA et al.: Specific phosphorylation of a site in the full-length form of the al subunit of the cardiac L-type calcium channel by adenosine 3),5)-cyclic monophos-phate dependent protein kinase. Biochemistry (1996) 35:10392–10402.
  • PERETS T, BLUMENSTEIN Y, SHISTIK E, LOTAN I, DASCAL N: A potential site of functional modulation by protein kinase A in the cardiac Ca 2+ channel a 1C subunit. FEBS Lett. (1996) 384:189–192.
  • ROTMAN El, DE JONGH KS, FLORIO, LAI Y, CATTERALL WA: Specific phosphorylation of a COOH-terminal site on the full-length form of the al subunit of the skeletal muscle calcium channel by cAMP-dependent protein kinase. j Biol. Chem. (1992) 267:16100–16105.
  • ROHRKASTEN A, MEYER HE, NASTAINCZYK W, SIEBER M, HOFMANN F: cAMP-dependent protein kinase rapidly phosphorylates serine-687 of the skeletal muscle receptor for calcium channel blockers. j Biol. Chem. (1988) 263:15325–15329.
  • BUNEMANN M, GERHARDSTEIN BL, GAO T, HOSEY MM: Functional regulation of L-type calcium channels via protein kinase A-mediated phosphorylation of the B2 subunit. J. Bia. Chem. (1999) 274:33851–33854.
  • JOHNSON BD, SCHEUER T, CATTERALL WA: Voltage-dependent potentiation of L-type calcium channels in skeletal muscle cells requires anchored cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA (1994) 91:11492–11496.
  • GAO T, YATANI A, DELL AC QUA ML et al.: cAMP-dependent regulation of cardiac L-type calcium channels requires membrane targeting of PKA and phosphorylation of channel subunits. Neuron (1997) 19:185–196.
  • WU Y, MACMILLAN LB, MCNEILL RB, COLBRAN, RJ, ANDERSON ME: CalVI kinase augments cardiac L-type Ca2+ current: a cellular mechanism for long Q-T arrhythmias. Am. J. Physid. (1999) 276(6-2):H2168–178.
  • LU HK, FERN RJ, LUTHIN D, LINDEN J: Angiotensin II stimulates T-type Ca2+ channel currents via activation of a G protein, Gi. Am. J Physiol. (1996) 271(4 Pt 1):C1340–1349.
  • YOKOSHIKI H, SUMII K, SPERELAKIS N: Inhibition of L-type calcium current in rat ventricular cells by the tyrosine kinase inhibitor, genistein and its inactive analog, daidzein. j Mol. Cell. Cardiol. (1996) 28:807–814.
  • WANG YG, LIPSIUS SL: Genistein elicits biphasic effects on L-type Ca 2+ current in feline atrial myocytes. Am. j Physiol. (1998) 275:H204–H212.
  • KWAN YW, QUI AD: Inhibition by extracellular ATP of L-type calcium channel currents in guinea-pig single sinoatrial nodal cells: involvement of protein kinase C. Can.. (1997) 13:1202–1211.
  • LACERDA AE, RAMPED, BROWN AM: Effects of protein kinase C activators on cardiac Ca2+ channels. Nature (1988) 335 (6187) :249–251.
  • SCHUHMANN K, GROSCHNER K: Protein kinase-C mediates dual modulation of L-type Ca2+ channels in human vascular smooth muscle. Febs Lett. (1994) 341(2-3):208–212.
  • SHISTIK E, IVANINA T, Y, DASCAL N: Crucial role of N-terminus in function of cardiac L-type calcium channel and its modulation by protein kinase C. j Biol. Chem. (1998) 273:17901–17909.
  • PURI TS, GERHARDSTEIN BL, ZHAO XL, LADNER MB, HOSEY MM: Differential effects of subunit interactions on protein kinase A- and C-mediated phosphorylation of L-type calcium channels. Biochemistry (1997) 36:9605–9615.
  • MCHUGH D, SHARP EM, SCHEUER T, CATTERALL WA: Inhibition of cardiac L-type calcium channels by protein kinase phosphorylation of two sites in the N-terminal domain. Proc. Nati Acad. Sci. USA (1994) 341(2-3):208–212.
  • SATOH H: Inhibition in L-type Ca2+ channel by stimulation of protein kinase C in isolated guinea pig ventricular cardiomyocytes. Gen. Pharmacol. (1992) 23:1097–1102.
  • JIANG LH, GAWLER DJ, HODSON N et al.: Regulation of cloned cardiac L-type calcium channels by cGMP-dependent protein kinase. j Biol. Chem. (2000) 275 (9) :6135–6143.
  • KIRSTEIN M, RIVET-BASTIDE M, HATEM S, BENARDEAU A et al.: Nitric oxide regulates the calcium current in 280 Op/n. Ther. Patents (2002) 12(2) human atrial myocytes. I OM. Invest. (1995) 95:794–802.
  • MOHAN E BRUTSAERT DL: Positive inotropic effect of nitric oxide in myocardium. Int. J. Cordial. (1995) 50:233–237.
  • BERKELS R, SUERHOFF S, ROESEN R, KLAUS W: Nitric oxide causes a cGMP-independent intracellular calcium rise in porcine endothelial cells-a paradox? Microvascular Res. (2000) 59(1):38–44.
  • CHIK CL, LIU QY, LI B, KARPINSKI E, HO AK: cGIVIP inhibits L-type Ca2+ channel currents through protein phosphorylation in rat pinealocytes. Neurosci. (1995) 15(4):3104–3109.
  • HAN X, KUBOTA I, FERON 0 et al.: Muscarinic cholinergic regulation of cardiac myocyte ICa-L is absent in mice with targeted disruption of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA (1998) 95:6510–6515.
  • YAMASHITA T, KAWASHIMA S, OZAKI, RIKITAKE Y: A calcium channel blocker, benidipine, inhibits intimal thickening in the carotid artery of mice by increasing nitric oxide production. J. Hypertens. (2001) 19(3):451–458.
  • NEHRA A, COLREAVY F, KHANDHERIA BK, CHANDRASEKARAN K: Sildenafil citrate, a selective phosphodiesterase Type 5 inhibitor: urologic and cardiovascular implications. World J. Ural. (2001) 19(1):40–45.
  • FLECKENSTEIN A, KAMMERMEIER H, DORING HJ, FREUND HJ: On the action mechanism of new coronary dilators with simultaneous oxygen saving myocardial effects, Prenylamine and Iproveratril. 1. Zeitschrift fur Kreislaufforschung (1967) 56(7):716–744.
  • KOHLHARDT M, BAUER B, KRAUSE H, FLECKENSTEIN A: Differentiation of the transmembrane Na and Ca channels in mammalian cardiac fibres by the use of specific inhibitors. Pllugers Archly. Eur. Physial.(1972) 335(4):309–322.
  • KUSUOKA H, CORRETTI MC, KORETSUNE Y, MARBAN E: Mechanism for the cardioprotective effects of the calcium channel blocker clentiazem during ischemia and reperfusion. Japanese Circ. J (1998) 62(8):611–616.
  • ROVNYAK GC, KIMBALL SD, BEYER B et al.: Calcium entry blockers and activators: conformational and structural determinants dihydropyrimidine calcium channel modulators. J. Med. Chem. (1995) 38(1):119–129.
  • TRIGGLE DJ, RAMPED: 1,4-Dihydropyridine activators and antagonists: structural and functional distinctions. Trend s Pharmacolog. Li. (1989) 10(12):507–511.
  • HESS P, LANSMAN JB, TSIEN RW: Different modes of Ca channel gating behaviour favoured by dihydropyridine Ca agonists and antagonists. Nature (1984) 311:538–544.
  • SANGUINETTI MC, KASS RS: Voltage-dependent block of calcium channel current in calf Purkinje fiber by dihydropyridine calcium channel antagonists. Circ. Res. (1984) 55:336–348.
  • HERING S, ACZEL S, KRAUS RL, BERJUKOW S: Molecular mechanism of use-dependent calcium channel block by phenylalkylamines: role of inactivation. Proc. Natl. Acad. Sci. USA (1997) 94(24):13323–13328.
  • HERING S, BERJUKOV S, ACZEL S, TIMIN EN: Calcium channel block and inactivation: Common molecular determinants. Trends Pharmacal. Li. (1998) 19:439–434.
  • HERING S, ACZEL S, KRAUS RL, BERJUKOW S: Molecular mechanism of use-dependent calcium channel block by phenylalkylamines: role of inactivation. Proc. Natl. Acad. Sci. USA (1997) 94(24):13323–13328.
  • STRIESSNIG J, GRABNER M, MITTERDORFER J et al.: Structural basis of drug binding to L calcium channels. Trends Pharmacal. Li. (1998) 19:108–115.
  • ••Comprehensive review.
  • HOCKERMAN, GH, DILMAC N, SCHEUER T, CATTERALL WA: Molecular determinants of diltiazem block in domains IIIS6 and IVS6 of L-type Ca2+ channels. Mal. Pharmacal. (2000) 58(6):1264–1270.
  • GODFRAIND T: Selectivity of calcium antagonists in the human cardiovascular system based on in vitro studies. J. Cardiovasc. Pharmacal. (1992) 20(5):534–S41.
  • INOMATA H, KAO CY: Ionic of repolarization in the guinea-pig taenia coil as revealed by the actions of strontium. J. Physial (1979) 297:443–462.
  • KATZ AM: Molecular basis of calcium channel blockade. Am. J. Cordial. (1992) 69(13):17E-22E.
  • HELD PH, YUSUF S: Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur. Heart J (1993) (Suppl. 9:18–25.4A.
  • ELKAYAM U, SHOTAN A, MEHRA A, OSTRZEGA E: Calcium channel blockers in heart failure. J. Am. College of Cardial. (1993) 4(Suppl. A):139A–144A.
  • RASPA RF, WILSON CC: Calcium channel blockers in the treatment of hypertension. Am. Family Physician (1993) 48(3):461–470.
  • KASTRUP EK, BURNHAM TH, HEBEL SK et al.: Drug Facts and Comparisons. Facts and Comparisons. St. Louis, Mo, olters Kluwer Company. (2000):149-149a.
  • STRAKA RJ, WANSON AL: Calcium Channel Antagonists: Morbidity and Mortality-What's the Evidence? Am. Family Physicians (1998) April 1.
  • GOODMAN, GILMAN AG: The Pharmacological Basis of Therapeutics (9th edition), Hardman JG, Gilman AG, Limbird LE (Eds.), McGraw-Hill, New York, (1995).
  • KATZUNG BG: Basic and Clinical Pharmacology (7th edition), Katzung BG (Ed.) Appleton & Lange, Norwalk, CN, USA, (1998).
  • TOYO-OKA T, Nayler WG: Third generation calcium entry blockers. Blood Pressure (1996) 5(4):206–208.
  • KELLY JG, O'MALLEY K: Clinical pharmacokinetics of calcium antagonists: an update. OM. Pharmacakinet. (1992) 22:416–421.
  • DOLLERY CT: Clinical pharmacology of the calcium antagonists. Am. J. Hyperten. (1991) 4:88S–95S.
  • SOGABE T, MORI T, OHURA M, TOMINAGA M: Venodilatory effect of pranidipine, a calcium channel blocker, monitored with perfluorocarbon in vivo (19)F-NMR spectroscopy. Magnetic Resonance Imaging (2000) 18(8):1011–1016.
  • MORI T, TAKASE H, TOIDE K et al.: Pranidipine, a 1,4-dihydropyridine calcium channel blocker that enhances nitric oxide-induced vascular relaxation. Cardiovasc. Drug Rev. (2001) 19(1):1–8.
  • MORI T, TAKEUCHI T, OHURA M, MIYAKODA G: Pranidipine, a new 1,4-dihydropyridine calcium channel blocker, enhances cyclic GMP-independent nitric oxide-induced relaxation of the rat aorta. Cellular Biochem. (1998) 178(1-2):335–343.
  • NISHIKAWA M, KUBO Y, JUDO H, NAKAYAMA T, NAKAMURA N: Protection against endothelial abnormalities by a novel calcium channel blocker, AE0047, in stroke-prone spontaneously hypertensive rats. General Pharmacol(1999) 32(3):299–305.
  • DEANA R, PANTO L, CANCELLOTTI FM, QUADRO G, GALZIGNA L: Properties of a new calcium ion antagonist on cellular uptake and mitochondrial efflux of calcium ions. Biochem. J. (1984) 218(3):899–905.
  • SHIRAHASE H, WADA K, UEHARA Y, NAKAMURA S, ICHIKAWA A: Preventive effect of iganidipine on renal and cerebral injuries in salt-induced hypertension. Am. J. Hyperten. (1997) 10(8):869–878.
  • WAKI M, SUGIYAMA T, WATANABE N et al.: Effect of topically applied iganidipine dihydrochloride, a novel calcium, on optic nerve head circulation in rabbits. Japanese J. Ophthalmology (2001) 45(1):76–83.
  • YAMAMOTO T, NIWA Y, KAWAKAMI H, KITAZAWA Y: The effect of nilvadipine, a calcium-channel blocker, on the hemodynamics of retrobulbar vessels in normal-tension glaucoma J. Glaucoma (1998) 7(5):301–305.
  • KAWABATA M, OGAWA T, T: Effects of lemildipine, a new calcium channel blocker, on renal microcirculation in SHR. Hypertension Res. (1998) 21(2):121–126.
  • ICHIHARA K, OKUMURA K, KAMEI H, NAGASAKA M: Renal effects of the calcium channel blocker aranidipine and its active metabolite in anesthetized dogs and conscious spontaneously hypertensive rats. Cardiovasc. Pharmacol (1998) 31(2):277–285.
  • LORTON D: P-Amyloid-induced IL-1I3 release from an activated human monocyte cell line is calcium- and G-protein-dependent. Mech. Ageing Dev. (1997) 94(1-3):199–211.
  • BHATIA R, LIN H, LAL R: Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for APP channel-mediated cellular toxicity. FASEB J. (2000) 14(9):1233–1243.
  • KANWAR U, ANAND RJ, SANYAL SN: The effect of nifedipine, a calcium channel blocker, on human spermatozoal functions. (1993) 48(5):453–470.
  • BENOFF S, COOPER GW, HURLEY I, MANDEL FS: The effect of calcium ion channel blockers on sperm fertilization potential. Fertility Sterility (1994) 62(3):606–617.
  • LEVINE LA, MERRICK PE LEE RC: Intralesional verapamil injection for the treatment of Peyronie's disease. J. Ural (1994) 151(6):1522–1524.
  • LEE RC, PING JA: Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J. Surg. Res. (1990) 49:463–466.
  • DOONG H, DISSANAYAKE TR, LABARBERA MC et al: Calcium antagonists alter cell shape and induce procollagenase synthesis in keloid and normal human dermal fibroblasts. J. Burn Care Rehab. (1996) 17:497–514.
  • CRISTOFORI P, LANZONI A, QUARTAROLI M et al.: The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J. Hyperterts. (2000) 18(10):1429–1436.
  • LEONE M, D'AMICO D, FREDIANI E MOSCHIANO F: Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. Neurology (2000) 54(6):1382–1385.
  • HOLLISTER LE, TREVINO ESG: Calcium Channel Blockers in Psychiatric Disorders: A Review of the Literature. Can. J. Psychiatry (1999) 44:658–664.
  • ••Comprehensive review.
  • HOFFMEISTER E TETTENBORN D: Calcium agonists and antagonists of the dihydropyridine type: antinociceptive effects, interference with opiate-mu-receptor agonists and neuropharmacological actions in rodents. Psychopharmacology (1986) 90(3):299–307.
  • COHEN CJ, SPIRES S, VAN SKIVER D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J. General Physiol. (1992) 100(4):703–728.
  • MATLIB MA: Action of bepridil, a new calcium channel blocker on oxidative phosphorylation, oligomycin-sensitive adenosine triphosphatase activity, swelling, Ca++ uptake and Na+-induced Ca++ release processes of rabbit heart mitochondria in vitro. J. Pharmacol Exp. Ther. (1985) 233(2):376–381.
  • NAGASHIMA S, UEMATSU T, ARAKI S, T: Bepridil hydrochloride alters potential-dependent and receptor-operated calcium channels in vascular smooth muscle of rabbit aorta. J. Pharmacol Exp. Ther. (1985) 234(1):63–71.
  • LEHNING EJ, DOSHI R, ISAKSSON N, STYS PK, LOPACHIN RIVI: Mechanisms of injury-induced calcium entry into peripheral nerve myelinated axons: role of reverse sodium-calcium exchange. J. Neurochem. (1996) 66(2):493–500.
  • WOLF JA, STYS PK, LUSARDI T, MEANEY D, SMITH DH: Traumatic axonal injury induces calcium influx modulated by tetrodotoxin-sensitive sodium channels. J. Neurosci. (2001) 21(6):1923–1930.
  • BROWN AM, WESTENBROEK RE, CATTERALL WA, RANSOM BR: Axonal L-type Ca2+ channels and anoxic injury in rat CNS white matter. J. Neurophysiol. (2001) 85(2):900–911.
  • CLOZEL JP, ERTEL EA, ERTEL SI: Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. I Hyperterts. (1997) 15(5):517–25.
  • SANDMANN ST, UNGER T: L- and T-type calcium channel blockade - the efficacy of the calcium channel antagonist mibefradil. I Gin Basic Cardiol (1999) 2:187.
  • OSTERRIEDER W, HOLCK M: In vitro pharmacologic profile of, a novel Ca2+ channel blocker with potent vasodilator but weak inotropic action. J. Cardiovasc. Pharmacol. (1889) 13:754–759.
  • SANDMANN S, BOHLE RIVI, DREYER T, UNGER T: The T-type calcium channel blocker mibefradil reduced interstitial and perivascular fibrosis and improved hemodynamic parameters in myocardial infarction-induced cardiac failure in rats. Virchows Archiv. (2000) 436(2):147–157.
  • MASON RP, MAK IT, WALTER MF, TULENKO TN, MASON PE: Antioxidant and cytoprotective activities of the calcium channel blocker mibefradil. Biochem. Pharmacol (1998) 55(11):1843–1852.
  • MILLER AL, LANGTON PD: inhibition of myogenic tone, K+-induced force and block of L-type calcium current in rat cerebral arteries. J. Physiol (1998) 508(Pt 3):793–800.
  • DEL POZO E, BAEYENS JM: Effects of calcium channel blockers on neuromuscular blockade induced by aminoglycoside. Eur. j Pharmacal (1986) 128(1-2):49–54.
  • PARADELIS AG, TRIANTAPHYLLIDIS CJ, MIRONIDOU M et al.: Interaction of aminoglycoside antibiotics and calcium channel blockers at the neuromuscular junctions. Meth. Flitclihgs Exp. Clin. Pharmacal (1988) 10(11):687–690.
  • KNAUS HG, STRIESSNIG J, KOZA A, GLOSSMANN H: Neurotoxic aminoglycoside antibiotics are potent inhibitors of 1125I1-Omega-Conotoxin GVIA binding to guinea-pig cerebral cortex membranes. Naunyn-Schmiedebergs Arch. Pharmacal (1987) 336(5):583–586.
  • REYNOLDS IJ, GOULD RJ, SNYDER SH: Loperamide: blockade of calcium channels as a mechanism for antidiarrheal effects. J. Pharmacal Exp. Ther. (1984) 231(3):628–632.
  • 00MS LA, DEGRYSE AD, JANSSEN PA: Mechanisms of action of loperamide. Scand. Castroenteral (1984) 96:145–155.
  • CHURCH J, FLETCHER EJ, ABDEL-HAMID K, MACDONALD JF: Loperamide blocks high-voltage-activated calcium channels and N-methyl-D-aspartate-evoked responses in rat and mouse cultured hippocampal pyramidal neurons. Mal Pharmacal (1994) 45(4):747–757.
  • CHAN E CHIU WT, CHEN YJ, WU PJ, CHENG JT: Calcium influx inhibition: possible mechanism of the negative effect of tetrahydropalmatine on left ventricular pressure in isolated rat heart. Planta Medico (1999) 65(4):340–342.
  • CHEN: Calcium antagonists from traditional Chinese herbs. Drug News Perspectives (1990) 3(7):425–428.
  • WANG G, LEMOS JR: Tetrandrine: a new ligand to block voltage-dependent Ca2+ and Ca(+) -activated K+ channels. Life Li. (1995) 56(5):295–306.
  • DONG H, EARLE ML, JIANG Y, LOUTZENHISER KA, TRIGGLE CR: Cardiovascular effects of CPU-23, a novel L-type calcium channel blocker with a unique molecular structure. Br J. Pharmacal (1997) 122(7):1271–1278.
  • TYTGAT J, VEREECKE J, CARMELIET E: Differential effects of verapamil and flunarizine on cardiac L-type and T-type Ca2+ channels. Naunyn-Schmiedeberg's Arch. Pharmacal (1988) 337:690–692.
  • GUBERT S, BRAS() MA, SACRISTAN A, ORTIZ JA: Synthesis of some N-benzhydrylpiperazine derivatives as calcium. Arzneimittel-Forschung (1987) 37(10):1103–1107.
  • TYTGAT J, PAUWELS PJ, VEREECKE J, CARMELIET E: Flunarizine inhibits a high-threshold inactivating calcium channel (N-type) in isolated hippocampal neurons. Brain Res. (1991) 17:549(1):112–117.
  • AKAIKE N, KOSTYUK PG, OSIPCHUK YV: Dihydropyridine-sensitive low-threshold calcium channels in isolated hypothalamic neurones. J. Physial (1989) 412:181–195.
  • RUIZ-NUNO A, VILLARROYA M, CANO-ABAD M et al: Mechanisms of blockade by the novel migraine prophylactic agent, dotarizine, of various brain and peripheral vessel contractility. Eur. Pharmacal (2001) 411(3):289–299.
  • SCHIERLE GS, BRUNDIN P: Excitotoxicity plays a role in the death of tyrosine hydroxylase-immunopositive nigral neurons cultured in serum-free medium. Expl. Neural (1999) 157:338–348.
  • EICHLER ME, DUBINSKY JM, TONG J RICH KM: The ability of diphenylpiperazines to prevent neuronal death in dorsal root ganglion neurons in vitro after nerve growth factor deprivation and in vivo after axotomy. I Neurochem. (1994) 62:2148–2157.
  • GONCALVES T, CARVALHO OLIVEIRA CR: Antioxidant effect of calcium antagonists on microsomal membranes isolated from different brain areas. Eur. Pharmacy]. (1991) 204:315–322.
  • ALPS BJ, CALDER C, HASS WK, WILSON AD: Comparative protective effects of nicardipine, flunarizine, lidoflazine and nimodipine against ischaemic injury in the hippocampus of Mongolian gerbil. Br J. Pharmacy]. (1988) 93:877–883.
  • TORIU N, AKAIKE A, YASUYOSHI H et al.: Lomerizine, a Ca2+ channel blocker, reduces glutamate-induced neurotoxicity and ischemiaireperfusion damage in rat retina. Exp. Eye Res. (2000) 70(4):475–484.
  • TERLAND O, FLATMARK T: Drug-induced parkinsonism: cinnarizine and flunarizine are potent uncouplers of the vacuolar H+-ATPase in catecholamine storage vesicles. Neuropharmacology (1999) 38(6):879–882.
  • HARAGUCHI K, ITO K, KOTAKI H, SAWADA Y, IGA T: Prediction of drug-induced catalepsy based on dopamine D1,2, and muscarinic acetylcholine receptor occupancies. Drug Metab. Disposition (1997) 25(6):675–684.
  • TAKAHARA A, SUGIYAMA A, DOHMOTO H, YOSHIMOTO R, HASHIMOTO K: Electrophysiological and cardiohemodynamic effects of AH-1058, a new type calcium channel blocker, assessed by the in vivo canine model. I Pharmacy]. (2000) 83(2):107–112.
  • GARCIA J, BEAM KG: Calcium transients associated with the T type calcium current in myotubes. j Genera] Physial (1994) 104(6):1113–1128.
  • CHAN J, GREENBERG DA: SK&F 96365, a receptor-mediated calcium entry inhibitor, inhibits calcium responses to endothelin- I in NG108-15 cells. Biochem. Biophys. Res. Comm. (1991) 177(3):1141–1146.
  • MERRITT JE, ARMSTRONG WP, BENHAM CD etal.: SK&F 96365, a novel inhibitor of receptor-mediated calcium entry. Biochem. J. (1990) 271(2):515–522.
  • SIMON T, JAILON P: Hormone replacement therapy in postmenopausal womem at cardiovascular risk: epidemiology and clinical trials. Eur. Heart J. (2000) G2–G6.
  • FARHAT M, LAVIGNE M, RAMWELL P: The vascular protective effects of estrogen. FASEB J. (1996) 10:615–624.
  • COLLINS P, BEALE CM, ROSANO GM: Oestrogen as a calcium channel blocker. Eur. Heart J. (1996) 17:27–31.
  • GRADY D, RUBIN S, PETTITI D: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med (1992) 117:1016–1037
  • BOYER JC, MAGOUS R, CHRISTEN MO, BALMES JL, BALI JP: Contraction of human colonic circular smooth muscle cells is inhibited by the calcium channel blocker pinaverium bromide. Cell Cakium (2001) 29(6):429–438.
  • VON WEGERER J, HESSLINGER B, BERGER M, WALDEN J: A calcium antagonistic effect of the new antiepileptic drug lamotrigine. Eur. Neuropsychapharmacal (1997) 7(2):77–81.
  • TODOROVIC SM, LINGLE CJ: Pharmacological properties of T-type Ca2+ current in adult rat sensory neurons: effects of anticonvulsant and anesthetic agents. J. Neuraphysial (1998) 79(1):240–252.
  • AMBROSIO AF, SILVA AP, MALVA JO et al.: Carbamazepine inhibits L-type Ca2+ in cultured rat hippocampal neurons stimulated with glutamate receptor agonists. Neuropharmacology (1999) 38(9):1349–1359.
  • DOUGHTY JM, MILLER AL, LANGTON PD: Non-specificity of chloride channel blockers in rat cerebral arteries: block of the L-type calcium channel. j Physiol. (1998) 507(2):433–439.
  • LEWIS RJ, NIELSEN KJ, CRAIK DJ, LOUGHNAN ML: Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. Biol. Chem. (2000) 275(45):35335–35344.
  • RAMILO CA, ZAFARALLA GC, NADASDI L et al.: Novel a- and to-conotoxins from Conus striatus venom. Biochemistry (1992) 31(41):9919–9926.
  • OLIVERA BM: Conus Venom Peptides, Receptor and Ion Channel Targets, and Drug Design: 50 Million Years of Neuropharmacology. Md. Biol. Cell (1997) 8:2101–2109.
  • JONES RIVI, CARTIER GE, MCINTOSH JM eta].: Composition and therapeutic utility of conotoxins from genus Conus. Expert Opin. Ther. Patents (2001) 11(4):603–623.
  • ••The most recent and comprehensive reviewon conotoxins.
  • SLUKA KA. Blockade of calcium channels can prevent the onset of secondary hyperalgesia and allodynia induced by intradermal injection of capsaicin in rats. Pain (1997) 71(2):157–164.
  • NEBE J, VANEGAS H, SCHAIBLE HG: Spinal application of omega-conotoxin GVIA, an N-type calcium channel antagonist, attenuates enhancement of dorsal spinal neuronal responses caused by intra-articular injection of mustard oil in the rat. Exp. Brain Res. (1998) 120(1):61–69.
  • VALENTINO K, NEWCOMB R, GADBOIS T et al.: A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc. Natl. Acad. Sci. USA (1993) 90(16)7894–7897.
  • CRAIG AG, NORBERG T, GRIFFIN D, HOEGER C: Contulakin-G, an 0-glycosylated invertebrate neurotensin. Biol. Chem. (1999) 274(20):13752–13759.
  • FAINZILBER M, LODDER JC, VAN DER SCHORS RC, LI KW: A novel hydrophobic omega-conotoxin blocks dihydropyridine-sensitive channels. Biochemistry (1996) 35(26):8748–8752.
  • KOBAYASHI K, SASAKI T, SATO K, KOHNO T: Three-dimensional solution structure of omega-conotoxin TxVII, an L-type calcium channel blocker. Biochemistry (2000) 39(48):14761–14767.
  • PISER TM, LAMPE RA, KEITH RA, THAYER SA: Omega-grammotoxin SIA blocks multiple, voltage-gated, Ca2+ channel subtypes in cultured rat hippocampal neurons. Ma. Pharmacol. (1995) 48(1):131–139.
  • MCDONOUGH SI, LAMPE RA, KEITH RA, BEAN BP: Voltage-dependent inhibition of N- and P-type calcium channels by the peptide toxin omega-grammotoxin-SIA. Md. Pharmacol. (1997) 52(6):1095–1104.
  • NEWCOMB R, SZOKE B, PALMA A, WANG G: Selective peptide antagonist of the class E calcium channel from the venom of the tarantula Hysterocrates gigas. Biochemistry (1998) 37(44):15353–15362.
  • ORI M, IKEDA H: Spider Venoms and Spider Toxins. I Toxicol. (1998) 17(3):405–426.
  • ••Interesting review on spider toxins.
  • ADAMS ME, MINTZ IM, REILY MD, THANABAL V, BEAN BP: Structure and properties of omega-agatoxin IVB, a new antagonist of P-type calcium channels. Md. Pharmacol. (1993) 44(4):681–688.
  • TERAMOTO T, KUWADA M, NIIDOME T, SAWADA K: A novel peptide from funnel web spider venom, omega-Aga-TK, selectively blocks, P-type calcium channels. Biochem. Biophys. Res. Com. (1993) 196(1):134–140.
  • SULLIVAN JM, LASATER EM: Sustained and transient calcium currents in horizontal cells of the white bass retina. j Genera] Physiol. (1992) 99(1):84–107.
  • HAGIWARA K, SAKAI K, MIWA A, NAKAJIMA T: Complete amino acid sequence of a new type of neurotoxin from the venom of the spider Agelena opulent a. Biomed. Res. (1990) 11:181.
  • BOWERS CW, PHILLIPS HS, LEE P, JAN YN, JAN LY: Identification and purification of an irreversible presynaptic neurotoxin from the venom of the spider Hololena curta. Proc. Natl. Acad. Sci. USA (1987) 84(10):3506–3510.
  • LEUNG HT, BYERLY L: Characterization of single calcium channels in Drosophila nerve and muscle cells. Neurosci. (1991) 11(10):3047–3059.
  • LUNDY PM, HONG A, FREW R: Inhibition of a dihydropyridine, omega-conotoxin insensitive Ca2+ channel in rat synaptosomes by venom of the spider Hololena curta. Eur. j Pharmacol. (1992) 225 (1) :51–56.
  • LUNDY PM, FREW R: Evidence of mammalian Ca2+ channel inhibitors in venom of the spider Plectreurys tristis. Toxicon (1993) 31(10):1249–1256.
  • B0DI J, NISHIO H, ZHOU Y et al.: Synthesis of an 0-palmitoylated 44-residue peptide amide (PLTX II) blocking presynaptic calcium channels in Drosophila. Peptide Res. (1995) 8(4):228–235.
  • PENG K, CHEN XD, LIANG SP: The effect of Huwentoxin-I on Ca(2+) channels in differentiated NG108-15 cells, a patch-clamp study. Toxicon (2001) 39(4):491–498.
  • YOSHIOKA DM, CHIBA T, MATSUKAW AM, NISHIMURA M, AKIZAWA T: Diversity of Joro Spider Toxins. Cyber Congress on Analytical BioSciences (1997).
  • ••Interesting mini-review on spider toxins.
  • YASUDA O, MORIMOTO S, JIANG Bet al.: F52. a mamba venom toxin, is a specific blocker of the L-type calcium channels. Artery (1994) 21(5):287–302.
  • DE WEILLE JR, SCHWEITZ H, MAES P, TARTAR A, LAZDUNSKI M: Calciseptine, a peptide isolated from black mamba venom, is a specific blocker of the L-type calcium channel. Proc. Nati Acad. Li. USA (1991) 88(6):2437–2440.
  • YASUDA O, MORIMOTO S, CHEN Y et al.: Calciseptine binding to a 1,4-dihydropyridine recognition site of the L-type calcium channel of rat synaptosomal membranes. Biochem. Biophys. Res. Com. (1993) 194(2):587–594.
  • SCHWEITZ H, HEURTEAUX C, BOIS P et al: Calcicludine, a venom peptide of the Kunitz-type protease inhibitor family, is a potent blocker of high-threshold Ca2+ channels with a high affinity for L-type channels in cerebellar granule neurons. Proc. Nail. Acad. Sci. USA (1994) 91(3):878–882.
  • BROWN AM, YATANI A, LACERDA AE, GURROLA GB, POSSANI LD: Neurotoxins that act selectively on voltage-dependent cardiac calcium channels. Circ. Res. (1987) 61(4):I6–9.
  • POSSANI LD, MARTIN BM, YATANI A et al.: Isolation and physiological of taicatoxin, a complex toxin with specific effects on calcium channels. Toxicon (1992) 30(11):1343–1364.
  • FANTINI E, ATHIAS P, TIROSH R, PINS ON A: Effect of TaiCatoxin (TCX) on the electrophysiological, mechanical and biochemical characteristics of spontaneously beating ventricular cardiomyocytes. Md. Cellul. Biochem. (1996) 160–161:61–66.
  • GELFAND VI, BERSHADASKY AD: Microtubule dynamics: mechanism, regulation and function. Ann. Rev Cell Biol. (1991) 7:93–116
  • GROSS R, KAYSER M, SCHRAMM M, TANIEL R, THOMAS G: Cardiovascular effects of the calcium-agonistic dihydropyridine BAY K 8644 in conscious dogs. Arch. Int. (1985) 277(2):203–216.
  • SHELTON RC, GREBB JA, FREED WJ: Induction of seizures in mice by intracerebroventricular administration of the calcium channel agonist BAY k 8644. Brain Res. (1987) 402:399–402.
  • RAMPE D, LACERDA AE: A new site for the activation of cardiac calcium channels defined by the nondihydropyridine FPL 64176.j Pharmacol. Ex. Ther. (1991) 259(3):982–987.
  • ZHENG W, RAMPE D, TRIGGLE DJ: Pharmacological, radioligand binding, and electrophysiological characteristics of FPL 64176, a novel nondihydropyridine Ca2+ channel activator, in cardiac and vascular preparations. Md. Pharmacol. (1991) 40(5):734–741.
  • MURATA M, NAOKI H, IWASHITA T et al.: Structure of maitotoxim. I Am. Chem. Soc. (1993) 115:2060–2062.
  • ZHENG W, DEMATTEI JA, WU JP et al.: Complete relative stereochemistry of maitotoxin. I Am. Chem. Soc. (1996) 118:7946–7968.
  • FREEDMAN SB, MILLER RJ, MILLER DM, TINDALL DR: Interactions of maitotoxin with voltage-sensitive calcium channels in cultured neuronal cells. Proc. Nati Acad. Sci. USA (1984) 81(104582–4585.
  • TAKAHASHI M, OHIZUMI Y, YASUMOTO T: Maitotoxin, a Ca2+ channel activator candidate. I Biol. Chem. (1982) 257(13):7287–7289.
  • GUSOVSKY F, DALY JW: Maitotoxin: a unique pharmacological tool for research on calcium-dependent mechanisms. Biochem. Pharmacol. (1990) 39:1633–1639.
  • XI D, VAN DOLAH FM, RAMSDELL JS: Maitotoxin induces a voltage dependent membrane depolarization in GH4 pituitary cells via activation of type L voltage dependent calcium channels. I Biol. Chem. (1992) 267:25025–25031.
  • CATALDI M, SECONDO A, D'ALESSIO A etal.: Studies on maitotoxin-induced intracellular Ca(2+) elevation in chinese hamster ovary cells stably transfected with cDNAs encoding for L-type Ca(2+) channel subunits. I Pharmacol. Exp. Ther. (1999) 290(2):725–730.
  • SATAKE M, MACKENZIE L, YASUMOTO T: Identification of Protoceratium reticulatum as the biogenetic origin of yessotoxin. Natural Toxins (1997) 5(4):164–167.
  • DE LA ROSA LA, ALFONSO A, VILARISTO N, VIEYTES MR, BOTANA LM: Modulation of cytosolic calcium levels of human lymphocytes by yessotoxin, a novel marine phycotoxin. Biochem. Pharmacol. (2001) 61(7):827–833.
  • HOLMES MJ, LEWIS RJ, JONES A, HOY AW: Cooliatoxin, the first toxin from Coolia mamas (Dinophyceae). Natural Toxins (1995) 3(5):355–362.
  • SATAKE M, TUBARO A, LEE JS, YASUMOTO T: Two new analogs of yessotoxin, homoyessotoxin and 45-hydroxyhomoyessotoxin, isolated from mussels of the Adriatic Sea. Natural Toxins (1997) 5(3):107–110.
  • DAIGUJI M, SATAKE M, RAMSTAD H et al.: Structure and fluorometric HPLC determination of 1-desulfoyessotoxin, a new yessotoxin analog isolated from mussels from Norway. Natural Toxins (1998) 6(6):235–239.
  • CIMINIELLO P, FATTORUSSO E, FORINO M, POLETTI R, VIVIANI R: Structure determination of carboxyhomoyessotoxin, a new yessotoxin analogue isolated from adriatic mussels. Chem. Res. Tarim]. (2000) 13(8):770–774.
  • GUKOVSKAYA AS, TREPAKOVA ES, ZINCHENKO V1 KORYSTOV YN, BEZUGLOV VV: Effect of the sulfhydryl reagent thimerosal on cytosolic free Ca2+ and membrane potential of thymocytes. Biochim. Biophys. Acta (1992) 1111(1):65–74.
  • FEARON IM, PALMER AC, AJ, BALL SG, VARADI G, PEERS C: Modulation of recombinant human cardiac L-type Ca2+ channel al C subunits by redox agents and hypoxia.. (1999) 514(3):629–637.
  • VAUPEL DB, LANGE WR, LONDON ED: Effects of verapamil on morphine-induced euphoria, analgesia and respiratory depression in humans. I Pharmacol. Exp. Ther (1993) 267(3):1386–1394.
  • DAYER P, DESMEULES J, COLLART L: Pharmacology of tramadol. Drugs (1997) 53(2):18–24.
  • GUPTA MC, GARG SK: Effect of nimodipine, a dihydropyridine calcium channel antagonist, on the steady state pharmacokinetics of phenytoin (DPH) in rhesus monkeys. Methods and Findings in Exp. Clin Pharmacol. (1999) 21(6):453–455.
  • EDELMAN DA, PAUL RA: Does combination therapy with a calcium channel blocker and an ACE inhibitor have additive effects on blood pressure reduction? Intl Clin. Pic. (2000) 54(2):105–109.
  • YE ZG, VAN DYKE K: Reversal of chloroquine resistance in falciparum malaria independent of calcium channels. Biochem. Biophys. Res. Com. (1988) 155(1):476–481.
  • KAPLAN NM: The calcium channel blocker controversy. Hypertension Res. (1996) 19(2):57–64.
  • JOLLIS JG, SIMPSON RJJR, CHOWDHURY MK et al.: Calcium channel blockers and mortality in elderly patients with myocardial infarction. Arch. Intern. Med. (1999) 159(19)2341–2348.
  • KIZER JR, KIMMEL SE: Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards. Arch. Intern. Med (2001) 161(9):1145–1158.
  • FRITZE J, WALDEN J: Clinical findings with nimodipine in dementia: test of the calcium hypothesis. I Neural Trans. (1995) 46:439–453.
  • HUANG HM, OU HC, HSIEH SJ: Antioxidants prevent amyloid peptide-induced apoptosis and alteration of calcium homeostasis in cultured cortical neurons. Life Sci. (2000) 66(19):1879–1892.

Websites

  • http://www.cpa-apc.org/Subscriptions/ Archives/ 191999/Sep/hollister.htm
  • http://neo.pharm.hiroshima-u.acjp/ccab/ 2nd/mini_review/mr121/yoshioka.html

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.